

Alaa A. Hassan,^{a*} Yusria R. Ibrahim,^a Ashraf A. Aly,^a Essmat M. El-Sheref,^a and Takehiko Yamato^b

^aChemistry Department, Faculty of Science, Minia University, El-Minia, Egypt


^bDepartment of Applied Chemistry, Faculty of Science and Engineering, Saga University, Saga, Japan

*E-mail: alaa Hassan2001@yahoo.com

Received June 24, 2010

DOI 10.1002/jhet.712

Published online 18 May 2013 in Wiley Online Library (wileyonlinelibrary.com).



The reaction of (substituted ethylidene)hydrazinecarbothioamides **4a–g** with dimethyl ethynedicarboxylate (DMAD, **2**) gave [(substituted ethylidene)hydrazono]-4-oxothiazolidine-5-ylidene]acetates **7a–g** (71–88 %). The structure of the new compounds was established by infrared spectroscopy, mass spectrometry, and NMR spectroscopy.

J. Heterocyclic Chem., **50**, 473 (2013).

INTRODUCTION

Reaction of unsubstituted thiourea with acetylene dicarboxylic methyl and ethyl esters could give rise to five- and six-membered heterocycles [1–3]. Unlike thioureas, the molecule of thiosemicarbazide contains four nucleophilic centers; therefore, the number of possible products that could be formed by the reactions of thiosemicarbazide derivatives with acetylene mono- and acetylene di-carboxylic acid esters increases [4,5].

Thiazolidinones and thiazinones were obtained by the reaction of thioureas and thiosemicarbazides with dimethyl ethynedicarboxylate (DMAD) [3,6–17]. The presence of an N–C–S linkage is believed to account for the amoebicidal, anticonvulsant, fungicidal [18], and antiviral [19] activities. Thiazolidin-4-one ring systems are known to act as analgesic, antibacterial, anticonvulsant, antiparasitic, anti-inflammatory, herbicidal [20–25], and potent anti-HIV agents [26].


Recently, we reported the reaction of various arenaldehyde 4-phenylthiosemicarbazones **1a–f** with DMAD (**2**) that gave methyl [3-aryl-4-oxo-1-(phenylthiocarbonyl)-4,5-dihydro-1*H*-pyrazol-5-ylidene]ethanoates **3a–f** [27]. Both the azomethine carbon and N2 of **1a–f** had taken part in the heterocyclization. Because DMAD (**2**) can offer only electrophilic sites for attack, the methine carbon of **1a–f** had acted as a nucleophile in sense of an “umpolung”. This behavior is not unexpected, because aldehyde hydrazones

are known to react as azaenamines toward suitable electrophiles [28]. This reactivity requires the availability of methine proton; the reactions reported are thus not open to ketone thiosemicarbazones. This fascinating versatility in the reaction of **1a–f** with **2** justifies of further investigation of the reactivity of ketone 4-unsubstituted and substituted thiosemicarbazones **4a–g** toward DMAD (**2**) (Scheme 1).

RESULTS AND DISCUSSION

Now we have reacted 2-(1-substituted ethylidene)hydrazinecarbothioamides **4a–g** (Fig. 1) with DMAD (**2**); the reactions gave mainly one single product each in 71–88% yield. From the elemental analyses and the mass spectra a net release of methanol (MW 32) had occurred.

In the infrared (IR) spectra, two carbonyl bands were observed in the ranges 1725–1715 cm^{-1} and 1705–1680 cm^{-1} , and a band between 1640 and 1620 cm^{-1} was assigned to C=N vibration. In the ^1H NMR spectra of all the compounds series **7a–d**, a NH proton appears at 13.06–12.92 ppm, accounting for lactam proton but not for imine proton, which is expected at upfield shift. This was considered to be a strong confirmation for the ring closure shown below in Scheme 4. The ^1H NMR spectra showed three singlets at 2.50–2.36, 3.89–3.83, and 6.94–6.73 ppm, because of



CH₃, methoxy protons, and vinyl-CH, respectively, in addition to the aromatic protons.

The *Z*-configuration of the exocyclic C=C bond, in the 5-benzylidene derivatives **7a–d** and **7e–g**, was attributed on the basis of ¹H-NMR spectral analysis, because the methine proton resonated as expected at higher chemical shift values 6.94–6.73 [11,29] because of the deshielding effect of the adjacent C=O than it would do in *E*-isomers.

In all cases of compounds **7a–g**, the ¹³C NMR have been obtained showing signals at 166.34–165.63, 165.99–164.0, 163.74–158.02, 159.34–153.66, 144.56–141.25, and 115.48–114.06 ppm because of (C=O, ring), (C=O, ester), (C-2), (external-C=N), (C-5), and (vinyl-CH), respectively. The ¹H-NMR spectrum of **7g** (R = phenyl, R' = allyl) clearly showed the presence of allyl group, which resonated at 4.57, 5.34, and 5.98 ppm because of (allyl-CH₂N), (allyl-CH₂=), and (allyl-CH=), respectively. The presence of allyl group is evident from the ¹³C-DEPT-NMR spectrum, exhibiting positive signal at 135.94 ppm (allyl-CH=) and negative signals at 44.96 and 118.27 ppm because of (allyl-CH₂N) and (allyl-CH₂=), respectively. The mass spectrometry fragmentations of the isolated compounds were studied under electron ionization. The mass spectra showed the following fragments common to all compounds [M⁺-15], 145 (C₅H₅SO₃), 72 (HCCO₂Me) and *m/z* 59 (CO₂Me). The composition listed may be reached in the following ways: it is likely that all products observed are formed from one of the three labile (1:1) adducts (**A**, **B**, and **C**) of **2** to **4a–g** (Scheme 2).

Likely isomeric products **5** and **6**, if the reaction took place through the intermediate (**A**), are shown in Scheme 3.




Figure 1. Substituted ethylidene hydrazinecarbothioamides **4a–g**.

The products **7** and **8** could be isolated, if the reaction involved the participation of SH and formation of intermediate (**B**) (Scheme 4).


If N4 attached the triple bond of **2** followed by intramolecular nucleophilic attack of N2 at ester group, the products **9** and **10** were formed *via* the intermediate (**C**) (Scheme 5).


The alternative structures **5**, **6**, **9**, and **10** could be ruled out on the basis of ¹³C NMR and the absence of C=S in the isolated products. The ring C=O resonances observed rule out the thiazine-4-one [6, 11] structure **8**, whereas they are agreeable for thiazolidin-4-ones **7** (Table 1).

However, only structures **7a–g** accommodates all spectral data listed above, especially the ¹³C-chemical shifts for ring carbonyl atoms, (C-2), (C-5), and vinyl-CH (Table 1) for comparison with all relevant and alternatives [10].

CONCLUSION

The products obtained from the reaction of (substituted ethylidene)hydrazinecarbothioamides **4a–g** with dimethyl ethynedicarboxylate (**2**), followed by heterocyclization are neither imidazolidinethione nor pyrimidinethione. Neither the N2-C(S)-N4 + C2 (intermediate **A**) nor the N4-C(S)-N2 + C2 (intermediate **C**) is observed due to the increased negative charge on sulfur atom, and S-C-N4 + C2 mode of cyclization is favored. Comparison of ¹³C NMR chemical shifts for the possible sets of isomers may serve as a useful supplementary tool in finding the correct structure of a heterocycle.





EXPERIMENTAL

Melting points were determined on using open capillaries on a Gallenkamp melting point apparatus and are uncorrected. The IR spectra were recorded with Shimadzu 408 instrument using potassium bromide plats. Spectra of 300 MHz ^1H NMR and 75 MHz ^{13}C NMR were recorded on Mercury-300BB spectrometers. Chemical shifts are expressed as δ (ppm) with reference of tetramethylsilane as internal standard, br = broad, s = singlet, dd = doublet of doublet, and m = multiplet. ^{13}C assignments (q = quaternary carbon atoms) were made with the aid of DEPT 135/90 spectra. The mass spectra (70 eV, electron impact mode) were recorded on Shimadzu Qp-2010 Plus instruments. Elemental analyses were carried out at the Microanalytical Center, Cairo University, Egypt. Thin-layer chromatography (TLC) was performed on analytical Merck 9385 Silica aluminum sheets (Kieselgel 60) with Pf_{254} indicator. TLCs were viewed at $\lambda_{\text{max}} = 254$ nm UV.

Starting materials. (Substituted ethylidene)hydrazinecarbothioamides **4a–g** were prepared by the reaction of thiosemicarbazide or 4-substituted thiosemicarbazides with the proper ketone, according to published procedures [30,31]. Dimethyl ethynedicarboxylate (DMAD, **2**) was bought from Fluka.

Reactions of (substituted ethylidene)hydrazinecarbothioamides **4a–g with dimethyl ethynedicarboxylate (DMAD, **2**).**
General procedure. To a solutions of (substituted ethylidene)hydrazinecarbothio-amides **4a–g** (2 mmol) in ethanol (25 mL) was added a solution of dimethyl ethynedicarboxylate (DMAD, **2**; 0.284 g, 2 mmol) in small portions. The mixture was stirring under reflux for 2–3 h (the reaction was followed by TLC). The solvent was evaporated and the residue was crystallized from suitable solvent to give compounds **7a–g**.

Methyl 2-[(Z)-2-((Z)-(1-phenylethylidene)hydrazono)-4-oxothiazolidin-5-ylidene]acetate (7a**).** This compound was obtained as yellow crystals (acetonitrile), mp 254–256 °C; ir: NH 3210–3150, CO 1720,




Table 1
 ^{13}C NMR shifts data in products **7a–g** (this work) and literature data of compounds comparable to **7a–g** and their structural alternatives.

| Compound | C-2 | C-4 | C-5 | Vinyl-CH | CO-ester | Literature data related to 8 | C-2 | C-4 | C-5 | CO-ester |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|---|--------|--------|--------|----------|
| 7a–g | 163.74 – 158.02 | 166.34 – 165.63 | 144.56 – 141.25 | 115.99 – 114.06 | 165.99 – 164.00 | Substituted thiazin-4-one [11] | 166.80 | 164.00 | 121.60 | 165.60 |
| Literature data related to 7a–g (4-oxothiazolidin-5-ylidene) acetate [10] | 160.95 | 166.80 | 144.10 | 115.42 | 164.47 | Benzimidazo-thiazin-4-one-2-carboxylate [6] | 142.70 | 159.00 | 121.30 | 161.60 |

1685, C=N 1640, Ar and C=C 1600, 1580 cm^{-1} ; ^1H NMR (DMSO- d_6): δ 2.4 (s, 3H, CH_3), 3.85 (s, 3H, OCH_3), 6.79 (s, 1H, vinyl-CH), 7.39 (m, 3H, Ar-H), 7.9 (m, 2H, Ar-H), 12.96 ppm (br s, 1H, NH); ^{13}C NMR (DMSO- d_6): δ 14.98 (CH_3), 52.27 (OCH_3), 114.67 (vinyl-CH), 126.74, 128.31, 130.16 (Ar-CH), 137.57 (Ar-C), 143.45 (C-5), 159.22 (acyclic-C=N), 162.98 (C-2), 165.99 (ester-CO), 166.34 (cyclic-CO); ms: m/z 303 (M^+ , 100), 288 (40), 244 (10), 216 (42), 186 (14), 145 (18), 118 (14), 77 (28), 72 (12), 59 (12). Anal. Calcd. for $\text{C}_{14}\text{H}_{13}\text{N}_3\text{O}_3\text{S}$: C, 55.43; H, 4.32; N, 13.85; S, 10.57. Found: C, 55.61; H, 4.17; N, 14.03; S, 10.69.

Methyl 2-[(Z)-2-((Z)-(1-(4-hydroxyphenyl)ethylidene)hydrazono)-4-oxothiazolidin-5-ylidene]acetate (7b). This compound was obtained as yellow crystals (acetonitrile), mp 272–274 °C; ir: HO 3495, NH 3195–3120, CO 1715, 1680, C=N 1635, Ar and C=C 1605, 1595 cm^{-1} ; ^1H NMR (DMSO- d_6): δ 2.41 (s, 3H, CH_3), 3.83 (s, 3H, OCH_3), 6.82 (s, 1H, vinyl-CH), 6.91 (dd, 2H, Ar-H), 7.81 (dd, 2H, Ar-H), 9.69 (s, 1H, OH), 12.92 ppm (br s, 1H, NH); ^{13}C NMR (DMSO- d_6): δ 14.26 (CH_3), 51.76 (OCH_3), 114.89 (vinyl-CH), 127.88, 128.04 (Ar-CH), 131.14 (Ar-C), 143.15 (C-5), 159.34 (acyclic-C=N), 162.50 (C-2), 165.50 (ester-CO), 165.80 (cyclic-CO); ms: m/z 319 (M^+ , 80), 304 (100), 232 (30), 227 (13), 134 (26), 145 (32), 92 (22), 77 (31), 72 (21), 59 (61). Anal. Calcd. for $\text{C}_{14}\text{H}_{13}\text{N}_3\text{O}_4\text{S}$: C, 52.66; H, 4.10; N, 13.16; S, 10.04. Found: C, 52.52; H, 4.19; N, 13.34; S, 9.91.

Methyl 2-[(Z)-2-((Z)-(1-(furan-2-yl)ethylidene)hydrazono)-4-oxothiazolidin-5-ylidene]acetate (7c). This compound was obtained as orange crystals (acetonitrile), mp 278–280 °C; ir: NH 3205–3150, CO 1715, 1690, C=N 1630, Ar and C=C 1610, 1595, C-O-C 1085 cm^{-1} ; ^1H NMR (DMSO- d_6): δ 2.36 (s, 3H, CH_3), 3.87 (s, 3H, OCH_3), 6.53 (m, 1H, furan-CH), 6.80 (s, 1H, vinyl-CH), 6.98 (m, 1H, furan-CH), 7.71 (m, 1H, furan-CH), 13.06 ppm (br s, 1H, NH); ^{13}C NMR (DMSO- d_6): δ 14.04 (CH_3), 51.87 (OCH_3), 111.64 (furan-CH), 114.06 (vinyl-CH), 112.29, 142.81 (furan-CH), 144.56 (C-5), 151.42 (furan-C), 154.03 (acyclic-C=N), 158.02 (C-2), 165.36 (ester-CO), 165.63 (cyclic-CO); ms: m/z 293 (M^+ , 56), 278 (33), 206 (23), 145 (18), 145 (22), 72 (42), 67 (21), 145 (18), 59 (30). Anal. Calcd. for $\text{C}_{12}\text{H}_{11}\text{N}_3\text{O}_4\text{S}$: C, 49.14; H, 3.78; N, 14.33; S, 10.93. Found: C, 48.95; H, 3.86; N, 14.51; S, 11.12.

Methyl 2-[(Z)-4-oxo-2-((Z)-(1-(pyridine-3-yl)ethylidene)hydrazono)thiazolidin-5-ylidene]acetate (7d). This compound was obtained as yellow crystals (acetonitrile), mp 256–258 °C; ir: NH 3230–3170, CO 1720, 1695, C=N 1625, Ar and C=C 1605, 1595 cm^{-1} ; ^1H NMR (DMSO- d_6): δ 2.5 (br, 3H, CH_3), 3.83 (s, 3H, OCH_3), 6.73 (s, 1H, vinyl-CH), 7.57 (m, 1H, pyridin-H), 8.26 (m, 1H, pyridin-H), 8.71 (m, 1H, pyridin-H), 9.09 (m, 1H, pyridin-H), 13.02 ppm (br s, 1H, NH); ^{13}C NMR (DMSO- d_6): δ 14.04 (CH_3), 51.87 (OCH_3), 114.06 (vinyl-CH), 143.36 (C-5), 142.2 (pyridine-C), 142.81, 144.56 (pyridine-CH), 151.42, 154.02 (pyridine-CH), 154.03 (acyclic-C=N), 159.14 (C-2), 165.37 (ester-CO), 165.63 (cyclic-CO); ms: m/z 304 (M^+ , 34), 289 (15), 217 (24), 159 (29), 145 (18), 85 (52), 119 (32), 78 (45), 72 (22), 59 (100). Anal. Calcd. for $\text{C}_{13}\text{H}_{12}\text{N}_4\text{O}_3\text{S}$: C, 51.31; H, 3.97; N, 18.41; S, 10.54. Found: C, 51.19; H, 4.08; N, 18.57; S, 10.36.

Methyl 2-[(Z)-4-oxo-3-phenyl-2((Z)-(1-phenylethylidene)hydrazono)thiazolidin-5-ylidene]acetate (7e). This compound was obtained as yellow crystals (acetonitrile), mp 198–200 °C; ir: Ar-CH 3100, CO 1725, 1695, C=N 1620, Ar and C=C 1605, 1585 cm^{-1} ; ^1H NMR (DMSO- d_6): δ 2.3 (s, 3H, CH_3), 3.89 (s, 3H, OCH_3), 6.94 (s, 1H, vinyl-CH), 7.41–7.58 (m, 8H, Ar-H), 7.85–7.91 ppm (m, 2H, Ar-H); ^{13}C NMR (DMSO- d_6): δ 14.6 (CH_3), 51.95 (OCH_3), 115.48 (vinyl-CH), 126.36, 126.95, 127.85, 128.42,

129.90 (Ar-CH), 133.62, 136.82 (Ar-C), 141.25 (C-5), 158.12 (acyclic-C=N), 163.91 (C-2), 164.35 (ester-CO), 165.84 (cyclic-CO); ms: m/z 379 (M^+ , 95), 364 (20), 320 (16), 292 (16), 261 (8), 234 (100), 135 (22), 145 (22), 118 (30), 77 (36), 72 (18), 59 (12). Anal. Calcd. for $\text{C}_{20}\text{H}_{17}\text{N}_3\text{O}_3\text{S}$: C, 63.31; H, 4.52; N, 11.07; S, 8.45. Found: C, 63.47; H, 4.41; N, 10.88; S, 8.34.

Methyl 2-[(Z)-3-benzyl-4-oxo-2-((Z)-(1-phenylethylidene)hydrazono)thiazolidin-5-ylidene]acetate (7f). This compound was obtained as yellow crystals (acetonitrile), mp 154–156 °C; ir: Ar-CH 3090, Ali-CH 2950, CO 1715, 1690, C=N 1620, Ar and C=C 1605, 1585 cm^{-1} ; ^1H NMR (DMSO- d_6): δ 2.48 (s, 3H, CH_3), 3.86 (s, 3H, OCH_3), 5.14 (s, 2H, CH_2), 6.89 (s, 1H, vinyl-CH), 7.36–7.49 (m, 8H, Ar-H), 7.90–7.92 ppm (m, 2H, Ar-H); ^{13}C NMR (DMSO- d_6): δ 14.46 (CH_3), 45.56 (CH_2), 51.76 (OCH_3), 114.92 (vinyl-CH), 126.32, 127.86, 127.91, 128.1, 128.22 (Ar-CH), 134.87, 136.72 (Ar-C), 141.83 (C-5), 153.66 (acyclic-C=N), 158.12 (C-2), 164.53 (ester-CO), 166.12 (cyclic-CO); ms: m/z 393 (M^+ , 56), 378 (31), 306 (52), 248 (33), 145 (100), 91 (71), 72 (18), 59 (21). Anal. Calcd. for $\text{C}_{21}\text{H}_{19}\text{N}_3\text{O}_3\text{S}$: C, 64.10; H, 4.87; N, 10.68; S, 8.15. Found: C, 63.94; H, 4.98; N, 10.82; S, 7.97.

Methyl 2-[(Z)-3-allyl-4-oxo-2-((Z)-(1-phenylethylidene)hydrazono)thiazolidin-5-ylidene]acetate (7g). This compound was obtained as yellow crystals (acetonitrile), mp 132–134 °C; ir: Ar-CH 3110, Ali-CH 2920, CO 1725, 1705, C=N 1630, Ar and C=C 1610, 1580 cm^{-1} ; ^1H NMR (DMSO- d_6): δ 2.49 (s, 3H, CH_3), 3.85 (s, 3H, OCH_3), 4.57 (m, 2H, allyl- CH_2N), 5.34 (m, 2H, allyl- CH_2), 5.98 (m, 1H, allyl- $\text{CH}=\text{C}$), 6.85 (s, 1H, vinyl-CH), 7.40–7.48 (m, 3H, Ar-H), 7.87–7.93 ppm (m, 2H, Ar-H); ^{13}C NMR (DMSO- d_6): δ 14.57 (CH_3), 44.96 (allyl- CH_2N), 51.95 (OCH_3), 115.12 (vinyl-CH), 118.27 (allyl- CH_2), 126.35, 126.56, 127.95 (Ar-CH), 129.94 (Ar-C), 135.94 (allyl- $\text{CH}=\text{C}$), 141.56 (C-5), 157.14 (acyclic-C=N), 163.74 (C-2), 164.00 (ester-CO), 165.66 (cyclic-CO); ms: m/z 343 (M^+ , 100), 328 (58), 256 (32), 198 (28), 145 (22), 118 (26), 77 (81), 72 (18), 59 (25), 41 (44). Anal. Calcd. for $\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}_3\text{S}$: C, 59.46; H, 4.99; N, 12.24; S, 9.34. Found: C, 59.61; H, 5.07; N, 12.12; S, 9.41.

REFERENCES AND NOTES

- [1] Vander Vliet, P. N. W.; Hawersma, J. A. M.; Speckamp, W. N. *Tetrahedron* 1985, 41, 2007.
- [2] Gianolla, L. I.; Palazzo, S.; Agozzino, P.; Lamartina, L.; Caraula, L. *J Chem Soc Perkin Trans* 1978, 1, 1428.
- [3] Vögeli, M.; Von Philipsborn, W.; Nagarajan, K.; Nair, M. D. *Helv Chim Acta* 1978, 61, 607.
- [4] Lown, J. W.; Ma, J. C. N. *Can J Chem* 1967, 45, 953.
- [5] Hiroshi, N. *Chem Pharm Bull* 1973, 21, 274.
- [6] Acheson, R. M.; Wallis, J. D. *J Chem Soc Perkin Trans* 1981, 1, 415.
- [7] Giammona, G.; Neri, M.; Carlisi, B.; Pazzo, A.; La Rosa, C. *J Heterocycl Chem* 1991, 28, 325.
- [8] Coen, S.; Ragonnet, B.; Vieillescazes, C.; Roggero, J. P. *Heterocycles* 1985, 23, 1225.
- [9] Tozkoparan, B.; Aktay, G.; Yesilada, E. *Farmaco* 2002, 51, 145.
- [10] Făbiân, B.; Csâmpai, A.; Nagy, T. Zs.; Czugler, M.; Sohâr, P. *J Organomet Chem* 2009, 694, 3732.
- [11] Făbiân, B.; Kudar, V.; Csâmpai, A.; Nagy, T. Zs.; Sohâr, P. *J Organomet Chem* 2007, 692, 5621.
- [12] Markovic, R.; Pergal, M. M.; Baranac, M.; Stanisavljev, D.; Stojanovic, M. *ARKIVOC* 2006, ii, 83.

- [13] Berseneva, V. S.; Morzherin, Y. Yu.; Dehaen, D.; Luyten, I.; Bakulev, V. A. *Tetrahedron* 2001, 57, 2179.
- [14] Aly, A. A.; Ahmed, E. K.; El-Mokadem, K. M. *J Heterocycl Chem* 2007, 44, 1431.
- [15] Fodor, L.; Gernäth, G.; Sohâr, P.; Gröschl, D.; Meier, H. *Monatsh Chem* 2006, 137, 231.
- [16] Csomös, P.; Fodor, L.; Bernäth, G.; Sinkkonen, J.; Salminen, J.; Wiinamäki, K.; Pihlaja, K. *Tetrahedron* 2008, 64, 1002.
- [17] Darehkordi, A.; Saidi, K.; Islami, M. R. *ARKIVOC* 2007, i, 180.
- [18] Joshi, H. D.; Upadhyay, P. S.; Baxi, A. J. *Indian J Chem* 2000, 39B, 976.
- [19] Al-Khamees, H. A.; Bayomi, S. M.; Kandil, H. A.; El-Thahir, K. *J Med Chem* 1990, 25, 103.
- [20] Kucu Kguzel, G.; Kocatepe, A.; Dlercq, E.; Sahin, F.; Gulluce, M. *Eur J Med Chem* 2006, 41, 353.
- [21] Tenorio, R. P.; Carvalho, C. S.; Pessanha, C. S.; de Lima, J. G.; de Faria, A. R.; Alves, A. J.; de Melo, E. J. T.; Goes, A. J. S. *Bioorg Med Chem Lett* 2005, 15, 2575.
- [22] Kato, T.; Ozaki, T.; Tsuzuki, K.; Ohi, N. *Org Process Res Dev* 2001, 5, 122.
- [23] Kucukguzel, S. G.; Oruc, E. E.; Rollas, S.; Sahin, F.; Ozbek, A. *Eur J Med Chem* 2002, 37, 197.
- [24] Shih, M. H.; Ke, F. Y. *Bioorg Med Chem* 2004, 12, 4633.
- [25] Kato, T.; Ozaki, T.; Tamura, K.; Szuzuki, Y.; Akima, M.; Ohi, N. *J Med Chem* 1999, 42, 3134.
- [26] Barreca, M. L.; Balzarini, J.; Chimirri, A.; De Clercq, E.; De Luca, L.; Holtje, H. D.; Holtje, M.; Monforte, A. M.; Monforte, P.; Pannecouque, C.; Rao, A.; Zappala, M. *J Med Chem* 2002, 45, 5410.
- [27] Hassan, A. A.; Shehata, H. S.; Döpp, D. *J Chem Res* 2008, 2, 725.
- [28] Brehme, R.; Enders, D.; Fernandez, R.; Lassaletta, J. M. *Eur J Org Chem* 2007, 5629.
- [29] Danikina, N. A.; Mikhailov, L. E.; Ivin, B. A. *Russ J Org Chem* 2006, 42, 783.
- [30] Sheibani, H.; Mosslemin, M. H.; Behzadi, S.; Islami, M. R.; Foroughi, H.; Saidi, K. *ARKIVOC* 2005, xv, 88.
- [31] Mostafa, H. A. *Electrochem Acta* 2000, 18, 45.